These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 35266417)

  • 61. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
    Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
    Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China.
    Xu Y; Mao N; Chirikov V; Du F; Yeh YC; Liu L; Liu R; Gao X
    Clin Drug Investig; 2019 Mar; 39(3):331-340. PubMed ID: 30684251
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G; Kappos L; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Ding N; Cohen JA;
    Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
    Papp V; Buron MD; Siersma V; Rasmussen PV; Illes Z; Kant M; Hilt C; Mezei Z; Roshanisefat H; Sejbæk T; Weglewski A; van Wingerden J; Geertsen SS; Bramow S; Sellebjerg F; Magyari M
    PLoS One; 2021; 16(5):e0250820. PubMed ID: 34003862
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The impact of relapse definition and measures of durability on MS clinical trial outcomes.
    Satyanarayan S; Cutter G; Krieger S; Cofield S; Wolinsky JS; Lublin F
    Mult Scler; 2023 Apr; 29(4-5):568-575. PubMed ID: 37119208
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
    N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis.
    Zagmutt FJ; Carroll CA
    Int J Neurosci; 2015; 125(11):798-807. PubMed ID: 25387069
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry.
    Hillert J; Tsai JA; Nouhi M; Glaser A; Spelman T
    Mult Scler; 2022 Feb; 28(2):237-246. PubMed ID: 34080926
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
    Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
    Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada.
    Bhan V; Clift F; Baharnoori M; Thomas K; Patel BP; Blanchette F; Adlard N; Vudumula U; Gudala K; Dutta N; Grima D; Mouallif S; Farhane F
    J Comp Eff Res; 2023 Sep; 12(9):e220175. PubMed ID: 37606897
    [No Abstract]   [Full Text] [Related]  

  • 72. It is time to rethink clinical trials on Bruton's tyrosine kinase inhibitors in multiple sclerosis.
    Barboza A
    Mult Scler Relat Disord; 2024 Feb; 82():105395. PubMed ID: 38184909
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative efficacy of ofatumumab
    Riley N; Drudge C; Nelson M; Haltner A; Barnett M; Broadley S; Butzkueven H; McCombe P; Van der Walt A; Wong EOY; Merschhemke M; Adlard N; Walker R; Samjoo IA
    Ther Adv Neurol Disord; 2024; 17():17562864241239453. PubMed ID: 38525490
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Teriflunomide in multiple sclerosis: an update.
    Miller AE
    Neurodegener Dis Manag; 2017 Feb; 7(1):9-29. PubMed ID: 27937746
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis.
    Saidha S; Bell J; Harold S; Belisario JM; Hawe E; Shao Q; Wyse K; Maiese EM
    Neurol Sci; 2023 May; 44(5):1515-1532. PubMed ID: 36648561
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses.
    Samjoo IA; Worthington E; Haltner A; Spin P; Drudge C; Cameron C; Brennan R; Dahlke F; Adlard N
    Curr Med Res Opin; 2021 Nov; 37(11):1933-1944. PubMed ID: 34384311
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis.
    Scott LJ
    Drugs; 2019 Jun; 79(8):875-886. PubMed ID: 31098896
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
    Guarnera C; Bramanti P; Mazzon E
    Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dimethyl fumarate and teriflunomide for multiple sclerosis in a real-life setting: a French retrospective cohort study.
    Condé S; Moisset X; Pereira B; Zuel M; Colamarino R; Maillet-Vioud M; Lauxerois M; Taithe F; Clavelou P;
    Eur J Neurol; 2019 Mar; 26(3):460-467. PubMed ID: 30320947
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A case of lymphoma in a patient on teriflunomide treatment for relapsing multiple sclerosis.
    Landais A; Alhendi R; Gouverneur A; Teron-Aboud B
    Mult Scler Relat Disord; 2017 Oct; 17():92-94. PubMed ID: 29055483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.